We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+25.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$288M
AUM Growth
+$45.4M
Cap. Flow
+$18.1M
Cap. Flow %
6.29%
Top 10 Hldgs %
61.77%
Holding
53
New
11
Increased
10
Reduced
18
Closed
13
Avg Time Held
5.9 quarters
Top 10 Avg Time Held
3.7 quarters
Top 20 Avg Time Held
6.2 quarters

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.63M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.58M
3
HROW icon
Harrow
HROW
+$5.15M
4
KALV icon
KalVista Pharmaceuticals
KALV
+$4.95M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$4.3M

Top Sells

Rank Stock Value
1
CUTR icon
Cutera, Inc.
CUTR
+$6.74M
2
INBX icon
Inhibrx, Inc. Common Stock
INBX
+$5.25M
3
MRUS icon
Merus
MRUS
+$5.07M
4
KROS icon
Keros Therapeutics
KROS
+$3.89M
5
MRSN icon
Mersana Therapeutics
MRSN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.08B
$55.7M 19.38%
3,775,000
+431,183
+13% +$5.15M
2018 Q3
17 quarters
TELA icon
2
TELA Bio
TELA
$48.3M
$23.8M 8.29%
2,072,813
+36,262
+2% +$325K
2019 Q4
12 quarters
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$6.05B
$21.4M 7.44%
735,000
-75,000
-9% -$1.93M
2022 Q2
2 quarters
OCUL icon
4
Ocular Therapeutix
OCUL
$1.62B
$17.1M 5.94%
6,075,000
-390,000
-6% -$1.29M
2019 Q1
15 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$13.4M 4.66%
732,000
+60,700
+9% +$1.07M
2021 Q1
7 quarters
CYTK icon
6
Cytokinetics
CYTK
$8.67B
$11.5M 3.98%
250,000
-13,000
-5% -$559K
2020 Q2
10 quarters
KROS icon
7
Keros Therapeutics
KROS
$226M
$11.4M 3.97%
238,000
-83,300
-26% -$3.89M
2021 Q1
7 quarters
PCVX icon
8
Vaxcyte
PCVX
$10.7B
$8.49M 2.95%
177,000
-13,000
-7% -$510K
2020 Q3
9 quarters
BHVN icon
9
Biohaven
BHVN
$1.72B
$7.5M 2.61%
+540,000
New +$7.63M
2022 Q4
0 quarters
FDMT icon
10
4D Molecular Therapeutics
FDMT
$686M
$7.33M 2.55%
330,000
-20,700
-6% -$320K
2021 Q4
4 quarters
TARA icon
11
Protara Therapeutics
TARA
$163M
$7.22M 2.51%
2,692,594
-15,473
-0.6% -$48.8K
2019 Q3
13 quarters
TCON
12
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$6.84M 2.38%
229,500
+20,000
+10% +$605K
2020 Q3
9 quarters
LRMR icon
13
Larimar Therapeutics
LRMR
$247M
$6.44M 2.24%
1,560,000
-101,784
-6% -$347K
2021 Q2
6 quarters
KALV icon
14
DELISTED
KalVista Pharmaceuticals
KALV
$6.24M 2.17%
+923,200
New +$4.95M
2022 Q4
0 quarters
ETON icon
15
Eton Pharmaceutcials
ETON
$1.56B
$6.12M 2.13%
2,170,000
-351,000
-14% -$944K
2018 Q4
16 quarters
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.09B
$5.47M 1.9%
611,400
-23,600
-4% -$221K
2022 Q1
3 quarters
PRQR icon
17
ProQR Therapeutics
PRQR
$217M
$5.4M 1.88%
1,460,000
-1,655,000
-53% -$2.17M
2021 Q1
7 quarters
PHAT icon
18
Phathom Pharmaceuticals
PHAT
$561M
$4.68M 1.63%
+417,500
New +$4.3M
2022 Q4
0 quarters
XOMA icon
19
DELISTED
Xoma
XOMA
$4.47M 1.55%
243,000
-5,000
-2% -$90.8K
2017 Q1
23 quarters
CDXS icon
20
Codexis
CDXS
$151M
$4.46M 1.55%
957,500
-197,500
-17% -$1.08M
2014 Q1
35 quarters
URGN icon
21
UroGen Pharma
URGN
$1.86B
$4.33M 1.51%
488,656
+91,156
+23% +$863K
2022 Q2
2 quarters
KPTI icon
22
Karyopharm Therapeutics
KPTI
$9.91M
$4.28M 1.49%
+80,456
New +$5.58M
2022 Q4
0 quarters
ATXS icon
23
DELISTED
Astria Therapeutics
ATXS
$3.9M 1.36%
261,703
+128,203
+96% +$1.32M
2022 Q3
1 quarter
LQDA icon
24
Liquidia Corp
LQDA
$2.38B
$3.57M 1.24%
560,000
-3,500
-0.6% -$18.8K
2021 Q4
4 quarters
ZNTL icon
25
Zentalis Pharmaceuticals
ZNTL
$233M
$3.37M 1.17%
+167,500
New +$3.6M
2022 Q4
0 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2022 Portfolio in Review

As of Q4 2022, Opaleye Management held 53 positions worth $288M, up 19% from $242M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management deployed $18.1M of net new capital in Q4 2022, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was Biohaven: 540,000 shares worth $7.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $3.89M trimmed.

  • Opaleye Management's largest Q4 2022 buy was Biohaven: 540,000 shares worth $7.5M.
  • Opaleye Management added most to Harrow in Q4 2022, an estimated $5.15M increase.
  • Opaleye Management's biggest Q4 2022 reduction was Keros Therapeutics, cutting an estimated $3.89M.
  • Opaleye Management fully exited Cutera, Inc. in Q4 2022, selling an estimated $6.74M.
  • Opaleye Management's ten largest holdings make up 62% of its $288M portfolio in Q4 2022.
  • Opaleye Management opened 11 new positions and closed 13 in Q4 2022.
  • Opaleye Management's portfolio value rose 19% quarter-over-quarter to $288M.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.